Start a discussion
Companies

GSK

PharmaceuticalsLondon, United KingdomGSK66,841 employees

Start a discussion

WorkHush has 1 source-backed update on GSK workforce changes since October 2026. The latest, added October 14, 2026: Up to 1,217 roles at risk in Belgium in R&D, manufacturing, support (confirmed reduction). Read it with sources ›

What the sources say

The source-backed update ›

Up to 1,217 roles at risk in Belgium in R&D, manufacturing, support

Confirmed reduction · Proposed Belgian job cuts reported by L'Echo and confirmed by a GSK spokesperson, October 14, 2026

Sources: Fierce Biotech

More about GSK

Drugmaker that develops and sells vaccines and specialty medicines for infectious diseases, HIV, cancer and respiratory conditions

Revenue
£32.7B
Fiscal 2025, up 4.1%
Employees
66,841
As of December 2025
Stock
GSK
New York Stock Exchange
Headquarters
London, United Kingdom
CEO
Luke Miels
Since January 2026
BrandsShingrix, Arexvy, Trelegy, Nucala, Dovato, ViiV Healthcare
Current strategyReallocating resources to specialty medicines and oncology deals ahead of HIV patent losses from 2028, targeting £40B in annual sales by 2031
Recent workforce changesThree-year plan announced in July 2026 to save about £1.9B a year, including unspecified job cuts and leaving its Stevenage research site
CompetitorsAstraZeneca, Pfizer, Sanofi
Related companiesAstraZenecaPfizerSanofi

Checked October 11, 2026 · Sources: sec.gov, biopharmadive.com

Be the first to post about GSK

No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.

Be the first to post

Or follow GSK to see the first post in your watchlist.

Follow GSK in a feed reader, no account needed: RSS feed